Amneal Pharmaceuticals, based in the United States, has announced plans to invest up to $200 million (approximately ₹1,680 crore) in India over the next four to five years. The investment will be directed toward the construction of two new manufacturing facilities in Ahmedabad. The planned greenfield sites will focus on peptide synthesis and advanced sterile fill-finish manufacturing, according to a company statement.
Co-founders and Co-CEOs Chirag Patel and Chintu Patel expressed their pride in this expansion, stating that the new facilities will enable Amneal to be at the forefront of developing and manufacturing innovative branded medicines at scale in India. These products are expected to serve both the local market and international markets.
Since beginning operations in India in 2008, Amneal has established eight manufacturing sites, including five in Ahmedabad, along with additional manufacturing facilities in Dahej, Hyderabad, and Visakhapatnam, as well as commercial offices in Mumbai. Over the past decade, the company has invested approximately $600 million in the country. Currently, its facilities boast the capacity to produce around 60 million units of injectables and 8.5 billion tablets annually.
.jpg "Artificial Intelligence to Revolutionize Advanced Chip Design")
